NuCana
In 2019, NuCana approached Oxford cancer researchers for clinical positioning input. They were supported from an initial 68 patient PK profiling study which was followed by combination studies and studies testing 2nd/3rd generation agents. In parallel mechanistic research was undertaken at the University that lead to the development of a companion diagnostic assay which was subsequently published and integrated into studies to help identify early signs of efficacy. Subsequently Nucana has gone on to launch an international registration phase 3 trial and is valued at IPO at $463M.